钠-葡萄糖协同转运蛋白2抑制剂治疗糖尿病视网膜病变的研究进展  

Research progress of sodium-glucose cotransporter 2 inhibitors in the treatment of diabetic retinopathy

作　　者：邹蔚文 雷茹雪 黄慧 郑燕林[2] ZOU Weiwen;LEI Ruxue;HUANG Hui;ZHENG Yanlin(Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province,China;Department of Ophthalmology,Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province,China)

机构地区：[1]成都中医药大学,四川省成都市610075 [2]成都中医药大学附属医院眼科,四川省成都市610075

出　　处：《眼科新进展》2024年第1期71-75,共5页Recent Advances in Ophthalmology

基　　金：四川省科技攻关计划项目(编号:2021MS124)。

摘　　要：糖尿病视网膜病变(DR)是一种常见的糖尿病并发症,钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂作为一种降糖药物被广泛用于糖尿病患者,对于DR的预防及治疗也有一定的作用,但目前关于SGLT-2抑制剂在DR临床治疗方面的作用尚未开展系统研究。因此,本文就SGLT-2抑制剂在DR治疗中的研究进展进行了综述,以期为DR的临床治疗提供更多的思路。Diabetic retinopathy(DR)is a common complication of diabetes.Sodium-glucose cotransporter 2(SGLT-2)inhibitors are widely used in diabetic patients as hypoglycemic drugs and also play a role in the prevention and treatment of DR.At present,there has been no systematic study on the clinical treatment of DR by SGLT-2 inhibitors.This paper reviews the research progress of SGLT-2 inhibitors in the treatment of DR,in order to provide more ideas for the clinical treatment of DR.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 糖尿病视网膜病变 研究进展 

分 类 号：R774[医药卫生—眼科]